Alba Cabirta

974 total citations
9 papers, 14 citations indexed

About

Alba Cabirta is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Alba Cabirta has authored 9 papers receiving a total of 14 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pathology and Forensic Medicine, 4 papers in Oncology and 3 papers in Genetics. Recurrent topics in Alba Cabirta's work include Lymphoma Diagnosis and Treatment (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and COVID-19 and healthcare impacts (2 papers). Alba Cabirta is often cited by papers focused on Lymphoma Diagnosis and Treatment (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and COVID-19 and healthcare impacts (2 papers). Alba Cabirta collaborates with scholars based in Spain, Belgium and Italy. Alba Cabirta's co-authors include Francesc Bosch, Pau Abrisqueta, Gloria Iacoboni, N. Raguer, Ana Marín‐Niebla, Rodrigo Dienstmann, David Valcárcel, Olga Salamero, Lucrecia Yáñez and Andrea Patriarca and has published in prestigious journals such as Blood, Annals of Oncology and Cancer Treatment Reviews.

In The Last Decade

Alba Cabirta

8 papers receiving 14 citations

Peers

Alba Cabirta

PFM

ONCOL

IMMUN

GENET

NEPHR

Christoph Plöger Germany

Peter Borchmann Germany

Giovanni Paolo Maria Zambrotta Italy

Spencer Henick Bachow United States

Daryl Ming Zhe Cheah Singapore

Trisha Mandal India

Hanna Weissbrot United States

Alexander Wald Germany

Priyadarshini Kumar United States

Ahmed Badr Egypt

Christoph Plöger Germany

Alba Cabirta

7 ×1.0

PFM

7 ×1.2

ONCOL

3 ×0.5

IMMUN

7 ×1.8

GENET

2 ×1.0

NEPHR

Citations per year, relative to Alba Cabirta Alba Cabirta (= 1×) peers Christoph Plöger

Countries citing papers authored by Alba Cabirta

Since Specialization

Citations

This map shows the geographic impact of Alba Cabirta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alba Cabirta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alba Cabirta more than expected).

Fields of papers citing papers by Alba Cabirta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alba Cabirta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alba Cabirta. The network helps show where Alba Cabirta may publish in the future.

Co-authorship network of co-authors of Alba Cabirta

This figure shows the co-authorship network connecting the top 25 collaborators of Alba Cabirta. A scholar is included among the top collaborators of Alba Cabirta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alba Cabirta. Alba Cabirta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Navarro, Vı́ctor, Gloria Iacoboni, Juan‐Manuel Sancho, et al.. (2024). Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes. Haematologica. 110(1). 173–178. 1 indexed citations

2.

Jiménez, Moraima, Alba Cabirta, Isabel Ruíz-Camps, et al.. (2023). Impact of COVID‐19 infection on bispecific antibodies treatment in patients diagnosed with B‐cell lymphoproliferative disorders. Hematological Oncology. 41(S2). 607–609. 1 indexed citations

3.

Abrisqueta, Pau, Ferran Nadeu, Gloria Iacoboni, et al.. (2023). From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia. Cancer Treatment Reviews. 120. 102619–102619. 4 indexed citations

4.

Lázaro, Carlos, Arnau Llauradó, Alba Cabirta, et al.. (2022). Síndrome de Guillain-Barré y trombocitopenia tras la vacunación contra el SARS-CoV-2 con Moderna. Descripción de un caso. Revista de Neurología. 75(8). 247–247. 2 indexed citations

5.

Grau‐López, Laia, Juan‐Manuel Sancho, Eva González‐Barca, et al.. (2022). Impact of Coronavirus (COVID-19) Pandemic on Maintenance Therapy for Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL). Blood. 140(Supplement 1). 9350–9352. 1 indexed citations

6.

Patel, Meera, Eudald Felip, Rachel Sharkey, et al.. (2021). 1588P SARS-CoV-2 antibody seroprevalence and safety of vaccines in cancer patients who recovered from COVID-19. Annals of Oncology. 32. S1142–S1142. 1 indexed citations

7.

Cabirta, Alba, Pau Abrisqueta, Sabela Bobillo, et al.. (2021). Early Relapse after First Line Has a Significant Impact on Overall Survival in Patients with Mantle Cell Lymphoma (MCL). Blood. 138(Supplement 1). 1357–1357. 2 indexed citations

8.

Jiménez, Moraima, Sabela Bobillo, Alba Cabirta, et al.. (2020). Real-World Data with the Use of Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). Blood. 136(Supplement 1). 14–16. 2 indexed citations

9.

Cabirta, Alba, Macarena Izuzquiza, Isabel Ruíz-Camps, et al.. (2020). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Hematologic Patients: Experience at the Hospital Attending More Patients in Spain. Blood. 136(Supplement 1). 30–31.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact